Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05146869
Other study ID # HA1118-014
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 30, 2021
Est. completion date March 28, 2022

Study information

Verified date April 2022
Source CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose and multiple-dose of DBPR108 tablets in Type 2 Diabetes Mellitus Patients.


Description:

This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, single-dose and multiple-dose of DBPR108 tablets in Chinese Type 2 Diabetes Mellitus Patients. The 30 eligible patients will be randomized to receive 50 mg, 100 mg, or 200 mg DBPR108 tablets.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 28, 2022
Est. primary completion date March 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients who meet the World Health Organization (WHO) (1999) criteria for the diagnosis and classification criteria for type 2 diabetes mellitus; 2. 18 = age = 75 years old, male or female; 3. Body mass index (BMI) within the range of 19-35 kg/m^2 (inclusive), BMI = weight (kg) / height^2 (m^2); 4. 7.0% =Hemoglobin A1c (HbA1c) = 9.5%; 5. Patients who voluntarily participate in the study and sign the informed consent form; 6. Patients who agree to use contraception from the signing of the informed consent form until 1 month after the end of the last medication. Exclusion Criteria: 1. Fasting plasma glucose (FPG) > 13.9 mmol/L; 2. The investigator determines that the patients need to use insulin therapy; 3. Patients with acute or serious complications of diabetes (including diabetic ketoacidosis, hyperosmotic nonketotic diabetic coma, lactic acidosis and hypoglycemia coma); 4. History of severe hypoglycemia (hypoglycemia with severe cognitive impairment and requiring other measures to help recover); 5. History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.); 6. History of allergy to DPP-4 inhibitors or the investigator determines that the patients may be allergic to investigational drug; 7. Patients with untreated hyperthyroidism and other diseases, which may affect blood glucose; 8. Patients who have used other hypoglycemic drugs within 14 days before the first dose; or patients who are not suitable for this study as determined by the investigator due to taking other hypoglycemic drugs; 9. Patients with inflammatory bowel disease, partial intestinal obstruction or chronic bowel disease related to obvious digestive and absorption disorders; 10. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 3 * upper limit of normal (ULN), or total bilirubin > 1.5 *ULN; 11. Abnormal renal function: serum creatinine>1.5 * ULN; or eGFR< 45 mL/min/1.73m^2; 12. White blood cells (WBC) < 3.0 *10^9/L and neutrophil count of peripheral blood < 1.5 * 10^9/L; hemoglobin < 100 g / L; triglyceride > 5.7 mmol/L; 13. Patients who have the second or third degree atrioventricular block, long Q-T syndrome, or QTc>500 ms without cardiac pacemaker; 14. Patients with any one of HBsAg, hepatitis C antibody, anti-HIV antibody and antibody of treponema pallidum positive; 15. Female patients of childbearing age with pregnant test positive or lactating women; 16. History of alcohol or drug abuse within 3 months before screening, alcohol abuse is average alcohol intake more than 14 units alcohol (1 unit=12 ounces or 360 mL of beer,1.5 ounces or 45 mL spirits with 40% alc/vol, 5 ounces or 150 mL grape wine); or intake any other products containing alcohol within 2 days before the first administration of investigational product; 17. Patients who smoke more than 5 cigarettes per day within 3 months prior to screening; 18. Patients with consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) within 2 days before the first administration in treatment period , or patients who have strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, etc; 19. Participation in other clinical trials or administration of any other investigational drugs or devices within 3 months before screening; 20. Patients with the following diseases: 1. Serious dysrhythmias, obvious left ventricular dysfunction, New York Heart Association (NYHA) functional class III or IV; 2. History of unstable angina pectoris, myocardial infarction, or other high-risk coronary artery diseases; 3. Uncontrolled hypertension, systolic pressure =160 mmHg or diastolic pressure =100 mmHg; 4. History of cancer , organ transplantation; 5. History of epilepsy, psychosis, severe depression, etc. 21. Not suitable for this study as determined by the investigator due to other reasons.

Study Design


Intervention

Drug:
DBPR108 tablets
DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.

Locations

Country Name City State
China Beijing Anzhen Hospital, Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak plasma concentration (Cmax) of DBPR108 tablets Cmax of DBPR108 tablets will be assessed after single-dose and multiple-dose administration Day 1-Day 11
Primary Area under the plasma concentration versus time curve (AUC) of DBPR108 tablets in plasma AUC of DBPR108 tablets will be assessed after single-dose and multiple-dose administration Day 1-Day 11
Primary Half-life(t1/2) of DBPR108 tablets T1/2 of DBPR108 tablets will be assessed after single-dose and multiple-dose administration Day 1-Day 11
Primary Apparent volume of Distribution(Vz/F)of DBPR108 tablets Vz/F of DBPR108 tablets will be assessed after single-dose and multiple-dose administration Day 1-Day 11
Primary CL/F of DBPR108 tablets Apparent clearance(CL/F) of DBPR108 tablets will be assessed single-dose and multiple-dose administration Day 1-Day 11
Primary Change from baseline in dipeptidyl peptidase-IV inhibition rate Change from baseline in dipeptidyl peptidase-IV inhibition rate will be assessed after single-dose and multiple-dose administration Day 1-Day 11
Primary Change from baseline in active glucagon-like peptide1 concentration Change from baseline in active glucagon-like peptide1 concentration will be assessed after single-dose and multiple-dose administration Day 1-Day 11
Secondary The number of patients with adverse events The number of patients with adverse events as a measure of safety and tolerability. Throughout the study period, with an average of 1 months
Secondary Clinically significant changes from baseline in 12-lead electrocardiogram (ECG) examination will be recorded as AEs at each visit time point ECG monitoring includes P-R, QT and QTc intervals in ms. Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11).
Secondary Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point. Vital signs monitoring includes respiratory rate and pulse in times per minute Throughout the study period, with an average of 1 months
Secondary Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point. Vital signs monitoring includes systolic blood pressure and diastolic blood pressure in mmHg. Throughout the study period, with an average of 1 months
Secondary Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point. Vital signs monitoring includes body temperature in degrees Celsius Throughout the study period, with an average of 1 months
Secondary Clinically significant changes from baseline in physical examination will be recorded as AEs at each visit time point. Physical examination includes mucocutaneous, lymphonodus, head and neck,chest, abdomen, spinal column, musculoskeletal, nervous system Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11).
Secondary Clinically significant changes from baseline in routine blood test will be recorded as AEs at each visit time point. Routine blood test includes white blood cell count, platelet, neutrophilic granulocyte count, lymphocyte count and monocyte count in 10^9 /L. Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)
Secondary Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point. Blood biochemistry test includes total protein, albumin and albumin in g/L. Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)
Secondary Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point. Blood biochemistry test includes alanine aminotransferase, aspartate aminotransferase, amylase, alkaline phosphatase and in U/L. Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)
Secondary Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point. Blood biochemistry test includes ureophil, glucose, triglyceridein, total cholesterol, high-density lipoprotein, low-density lipoprotein, sodium, potassium, chlorine, calcium in mmol/L Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)
Secondary Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point. Blood biochemistry test includes total bilirubin and serum creatinine in umol/L. Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day 11)
Secondary Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point. Routine urine test includes the count of leukocyte, and red blood cell in high-power field. Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)
Secondary Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point. Routine urine test includes glucose, protein, ketonein in negative or positive. Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance